

해외 바이오의약품 임상 현황 (2020.08.17~2020.08.23)

한국바이오의약품협회, 2020.8.25.
출처: ClinicalTrials.gov

○ 미국 11건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04524962	Study of Descartes-30 in Acute Respiratory Distress Syndrome	Acute Respiratory Distress Syndrome Covid19	Biological: Descartes 30	Cartesian Therapeutics	Phase 1 Phase 2
NCT04506567	Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC	Prostate Cancer	Drug: 225Ac-J591 Diagnostic Test: 68Ga-PSMA-HBED-CC injection	Weill Medical College of Cornell University	Phase 1 Phase 2
NCT04524507	COVID-19 Antibody Plasma Research Study in Hospitalized Patients	COVID-19	Biological: High-titer Convalescent COVID-19 Plasma (CCP1) Biological: Standard-titer Convalescent COVID-19 plasma (CCP2)	University of North Carolina, Chapel Hill	Phase 2
NCT04489420	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM	Astrocytoma, Grade IV Giant Cell Glioblastoma Glioblastoma Multiforme Cyclophosphamide Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Molecular Mechanisms of Pharmacological Action Antiviral Agents Anti-infective Agents Analgesics, Non-narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents	Biological: CYNK001-IV Biological: CYNK001-IT	Celularity Incorporated	Phase 1
NCT04370054	Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults	Hemophilia A	Biological: Recombinant AAV2/6 Human Factor VIII Gene Therapy	Pfizer	Phase 3
NCT04518410	A Study for Outpatients With COVID-19	Coronavirus Covid19	Drug: LY3819253 Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) Eli Lilly and Company AIDS Clinical Trials Group	Phase 2 Phase 3
NCT04381650	A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors	Advanced or Metastatic Solid Tumors	Drug: TAK-981 Drug: Pembrolizumab	Takeda Takeda Development Center Americas, Inc.	Phase 1 Phase 2
NCT04267237	A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer	Non-small Cell Lung Cancer (NSCLC)	Drug: Atezolizumab Drug: RO7198457	Hoffmann-La Roche	Phase 2
NCT04169711	Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma	Clear Cell Renal Cell Carcinoma	Drug: ARO-HIF2	Arrowhead Pharmaceuticals	Phase 1
NCT04516746	Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults	COVID-19 SARS-CoV-2	Biological: AZD1222 Biological: Placebo	AstraZeneca qvia Pty Ltd	Phase 3
NCT04489940	Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer	Triple Negative Breast Neoplasms	Drug: Bintrafusp alfa	EMD Serono Research & Development Institute, Inc. Merck KGaA, Darmstadt, Germany EMD Serono	Phase 2

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04507256	Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults	COVID-19	Combination Product: AZD7442 Other: Placebo	AstraZeneca Parxel	Phase 1

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04348045	Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients	Metastatic Pancreatic Adenocarcinoma	Drug: Arm A - Olaparib Drug: ARM B - durvalumab plus selumetinib Drug: ARM C FOLFIRI	GERCOR - Multidisciplinary Oncology Cooperative Group AstraZeneca	Phase 2

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04268823	Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	Drug: QBW251 Drug: Placebo	Novartis Pharmaceuticals Novartis	Phase 2

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04515927	To Evaluate the Efficacy and Safety of JS002 in HoFH Patients	Hyperlipemia	Drug: JS002	Shanghai Junshi Bioscience Co., Ltd.	Phase 2
NCT04321330	A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma	Carcinoma, Thymic	Drug: Atezolizumab	Hoffmann-La Roche	Phase 2

○ 일본 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04509947	A Study of Ad26.COV2.S in Adults (COVID-19)	Healthy	Biological: Ad26.COV2.S Biological: Placebo	Janssen Pharmaceutical K.K.	Phase 1
NCT04340193	A Study of Nivolumab and Ipilimumab in Combination With Transarterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer	Liver Cancer	Biological: nivolumab Biological: ipilimumab	Bristol-Myers Squibb	Phase 3
NCT04338269	A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment	Carcinoma, Renal Cell	Drug: Atezolizumab Drug: Cabozantinib	Hoffmann-La Roche Exelixis Chugai	Phase 3